Author/Editor		Tomažič, Janez; Vidmar, Ludvik; Čatak, Senka; Matičič, Mojca; Poljak, Mario; Ihan, Alojz
Title		Zdravljenje bolnikov, okuženih s HIV, s sakvinavirjem in dvema zaviralcema reverzne transkriptaze
Translated title		Treatment of patients infected with HIV with saquinavir and two reverse transcriptase inhibitors
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 36, št. Suppl
Publication year		1997
Volume		str. 187-92
Language		slo
Abstract		In a prospective study, clinical, virological and immunological effects of a three drug combination therapy (saquinavir + two reverse transcriptase inhibitors) was assesed over a period of 32 weeks in antiretroviral-treated HIV infected patients (n = 8) and in antiretroviral-naive HIV infected patients (n = 5). In a treated group, the decrease of the median plasma HIV-1 RNA level after 3 and 8 months of treatment was 0.53 log and 0.69 log. The mean increase in CD4+ count after 3 and 8 months was 31 and 29 cells/micro l. Disease progression occurred in two patients, one patient stopped saquinavir due to diarrhea. In the untreated group the decrease of the median plasma HIV-1 RNA level after 3 and 6 months was 1.3 log and 1.98 log. The mean increase in CD4+ count after 3 and 6 months was 72 and 103 cells/micro. There was no clinical deterioration in the follow up period in this group. In our pilot study, a combination of saquinavir with two nucleoside analogs reduced plasma HIV-1 RNA levels and increased CD4+ cell counts. It seems that adding saquinavir was more effective in patients with no previous antiretroviral treatment. In general, saquinavir was well tolerated.
Summary		Prospektivno smo ocenjevali klinične, virološke in imunološke učinke kombinacije treh protiretrovirusnih zdravil (sakvinavir + dva zaviralca reverzne transkriptaze) v obdobju 32 tednov, pri bolnikih okuženih s HIV ki so že bili na protiretrovirusnem zdravljenju (n = 8), in pri bolnikih okuženih s HIV, ki teh zdravil še niso prejemali (n = 5). Pri že zdravljenih bolnikih je prišlo po treh in osmih mesecih kombiniranega zdravljenja do padca mediane plazemske koncentracije HIV-1 RNA za log 0,53 in log 0,69 ter do povprečnega povečanja števila celic CD4+ za 31 in 29 celic/mikro. Pri dveh bolnikih je bolezen napredovala, en bolnik je zaradi driske prenehal jemati sakvinavir. Pri nezdravljenih bolnikih je po treh in šestih mesecih kombiniranega zdravljenja prišlo do padca mediane plazemske koncentracije HIV-1 RNA za log 1,3 in log 1,98 ter do porasta povprečnega števila celic CD4+ za 72 in 103 celic/mikro. V tej skupini bolnikov ni prišlo do kliničnega poslabšanja. V naši pilotski študiji je kombinacija sakvinavirja z dvema nukleozidnima analogoma zmanjšala koncentracijo HIV-1 RNA v plazmi in povečala koncentracije celic CD4+ v periferni krvi. Rezultati nakazujejo boljšo učinkovitost pri bolnikih, ki pred tem še niso prejemali protiretrovirusnih zdravil. V splošnem so bolniki sakvinavir dobro prenašali.
Descriptors		HIV INFECTIONS REVERSE TRANSCRIPTASE INHIBITORS SAQUINAVIR DRUG THERAPY, COMBINATION PROSPECTIVE STUDIES RNA HIV-1 CD4 LYMPHOCYTE COUNT